LEADER 04480oam 2200649Ma 450 001 9910455454703321 005 20190729113749.0 010 $a0-367-80057-8 010 $a1-280-10783-9 010 $a9786610107834 010 $a0-203-91003-6 010 $a0-8247-4681-3 035 $a(CKB)111004368683968 035 $a(EBL)215937 035 $a(OCoLC)54098476 035 $a(SSID)ssj0000209976 035 $a(PQKBManifestationID)11173235 035 $a(PQKBTitleCode)TC0000209976 035 $a(PQKBWorkID)10266781 035 $a(PQKB)10091743 035 $a(MiAaPQ)EBC215937 035 $a(Au-PeEL)EBL215937 035 $a(CaPaEBR)ebr10051410 035 $a(CaONFJC)MIL10783 035 $a(OCoLC)1055239434 035 $a(OCoLC-P)1055239434 035 $a(FlBoTFG)9780824746810 035 $a(EXLCZ)99111004368683968 100 $a20130805d1999 uy 0 101 0 $aeng 135 $aur||||||||||| 181 $ctxt 182 $cc 183 $acr 200 00$aNew and exploratory therapeutic agents for asthma /$fedited by Michael Yeadon, Zuzana Diamant 210 $aNew York $cMarcel Dekker ;$aBoca Raton, Fla. $cCRC Press$dİ1999 215 $a1 online resource (528 p.) 225 1 $aLung biology in health and disease ;$vv. 139 300 $aDescription based upon print version of record. 311 $a0-585-25139-8 311 $a0-8247-7861-8 327 $aINTRODUCTION; PREFACE; CONTRIBUTORS; CONTENTS; Epidemiology of Asthma; Pathophysiology of Asthma; Pathology of Asthma; Muscarinic Receptor Subtypes and Anticholinergic Therapy; Long-Acting BETA 2-Agonist Drugs; Inhaled Glucocorticoids, Established and New; Platelet-Activating Factor Antagonists in Bronchial Asthma; Tachykinin Receptor Antagonists; Therapeutic Potential of Phosphodiesterase Type 4 Inhibitors in the Treatment of Asthma; Leukotriene Modulators; The Anti-IgE Treatment Strategy for Asthma; Activity of T-Cell Subsets in Allergic Asthma; New Targets for Future Asthma Therapy 327 $aCurrent Practice and Future Trends in Clinical Trials in AsthmaAUTHOR INDEX ; SUBJECT INDEX 330 $aDiscusses three major classes of asthma therapies-bronchodilators, antiinflammatories, and antiallergics-as well as potential new therapeutic approaches!This comprehensive volume addresses the latest treatment strategies for asthma, keying in on the genetics and molecular biology of asthma and pointing the way toward new, commercially viable therapies.Presents the most up-to-date information available on the genetics, epidemiology, pathology, pharmacology, and pulmonology of asthma.Written by more than 20 leading international experts, New and Exploratory Therapeutic Agents for Asthmaexplores asthma both as incidence of dysfunctional airway smooth muscle and as a disorder of the immune system examines the role of monoclonal antibodies in allergy and asthma describes functions and pharmacokinetic profiles of bronchodilator 2 agonists, anticholinergics, and inhaled glucocorticosteroids investigates the controversy of different types of asthma illustrates the connections between clinical symptoms and the immunopathology of eosinophilic inflammation assesses prospects for the development of a successful oral anti-inflammatory therapy, an immunomodulator that lowers antigen-specific IgE, an anticytokine compound, and an agent that safely combines bronchospasmolytic and anti-inflammatory properties reviews the impact of the recent introduction of antileukotriene agents, clinical findings with PAF antagonists, and selective antimuscarinics evaluates the relationship between improvements in laboratory results and clinical effectiveness and more!Containing over 2000 bibliographic citations and a concise introduction for each chapter, New and Exploratory Therapeutic Agents for Asthma is indispensable for pulmonologists, pediatricians, physiologists, immunologists, allergists, pharmaceutical industry scientists, primary care physicians, and medical s 410 0$aLung biology in health and disease ;$vv. 139. 606 $aAntiasthmatic agents 608 $aElectronic books. 615 0$aAntiasthmatic agents. 676 $a616.2/3806 701 $aYeadon$b Michael$01050123 701 $aDiamant$b Zuzana$01050124 801 0$bOCoLC-P 801 1$bOCoLC-P 906 $aBOOK 912 $a9910455454703321 996 $aNew and exploratory therapeutic agents for asthma$92479651 997 $aUNINA